ATE276756T1 - Verwendung des heregulins als epithelzellenwachstumsfaktor - Google Patents

Verwendung des heregulins als epithelzellenwachstumsfaktor

Info

Publication number
ATE276756T1
ATE276756T1 AT99905717T AT99905717T ATE276756T1 AT E276756 T1 ATE276756 T1 AT E276756T1 AT 99905717 T AT99905717 T AT 99905717T AT 99905717 T AT99905717 T AT 99905717T AT E276756 T1 ATE276756 T1 AT E276756T1
Authority
AT
Austria
Prior art keywords
cell growth
epithelial cell
heregulin
growth factor
her3
Prior art date
Application number
AT99905717T
Other languages
English (en)
Inventor
Mark Sliwkowski
Jeffrey A Kern
Original Assignee
Genentech Inc
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Univ Iowa Res Found filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE276756T1 publication Critical patent/ATE276756T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99905717T 1998-02-04 1999-02-03 Verwendung des heregulins als epithelzellenwachstumsfaktor ATE276756T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2059898A 1998-02-04 1998-02-04
PCT/US1999/002390 WO1999039729A2 (en) 1998-02-04 1999-02-03 Use of heregulin as an epithelial cell growth factor

Publications (1)

Publication Number Publication Date
ATE276756T1 true ATE276756T1 (de) 2004-10-15

Family

ID=21799510

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04022325T ATE438720T1 (de) 1998-02-04 1999-02-03 Verwendung des heregulins als epithelzellenwachstumsfaktor
AT99905717T ATE276756T1 (de) 1998-02-04 1999-02-03 Verwendung des heregulins als epithelzellenwachstumsfaktor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04022325T ATE438720T1 (de) 1998-02-04 1999-02-03 Verwendung des heregulins als epithelzellenwachstumsfaktor

Country Status (10)

Country Link
US (1) US20020042087A1 (de)
EP (2) EP1510579B1 (de)
JP (1) JP4485051B2 (de)
AT (2) ATE438720T1 (de)
AU (1) AU2581599A (de)
CA (1) CA2318857C (de)
DE (2) DE69920405T2 (de)
DK (1) DK1510579T3 (de)
ES (2) ES2229679T3 (de)
WO (1) WO1999039729A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
DE60028970T2 (de) 1999-07-02 2007-02-15 Genentech Inc., San Francisco An her2 bindende peptidverbindungen
CN105802904B (zh) * 2006-02-23 2021-04-20 维亚赛特公司 用于培养可分化细胞的组合物和方法
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2744824A1 (de) * 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Neuregulin-antikörper und verwendungen davon
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US8791244B2 (en) 2011-09-30 2014-07-29 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727943A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
EP2727942A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
US20170333529A1 (en) * 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CN113789387B (zh) * 2021-11-15 2022-02-22 中国医学科学院北京协和医院 标志物在诊断腹主动脉瘤中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0350973B1 (de) 1983-09-26 1997-11-05 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
EP0970207B1 (de) * 1997-02-10 2009-04-01 Genentech, Inc. Heregulin varianten

Also Published As

Publication number Publication date
ATE438720T1 (de) 2009-08-15
DK1510579T3 (da) 2009-11-30
JP4485051B2 (ja) 2010-06-16
EP1510579A2 (de) 2005-03-02
ES2329467T3 (es) 2009-11-26
CA2318857A1 (en) 1999-08-12
ES2229679T3 (es) 2005-04-16
EP1053009B1 (de) 2004-09-22
DE69920405T2 (de) 2006-01-05
WO1999039729A3 (en) 1999-10-14
DE69920405D1 (de) 2004-10-28
EP1510579A3 (de) 2005-05-11
EP1510579B1 (de) 2009-08-05
WO1999039729A2 (en) 1999-08-12
US20020042087A1 (en) 2002-04-11
JP2002509076A (ja) 2002-03-26
AU2581599A (en) 1999-08-23
EP1053009A2 (de) 2000-11-22
CA2318857C (en) 2013-09-24
DE69941228D1 (de) 2009-09-17

Similar Documents

Publication Publication Date Title
ATE438720T1 (de) Verwendung des heregulins als epithelzellenwachstumsfaktor
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
GEP20105118B (en) Anti-vegf antibodies
TR199700584A2 (xx) Heterosiklik-kayna��k piridinler.
ATE381943T1 (de) Zellwachstumsinhibition
TR199902372A2 (xx) Sulfanilsilanlar.
ATE254613T1 (de) Bestimmte 1,4,5-trisubstituierte imidazoleverbindungen zur verwendung als cytokin
TR970073A2 (tr) Alfa adrenerjik resentör antagonistleri olarak pirimidindion pirimidintrion,triazindion, tetrahidrokinazolindion türevleri.
BR9810342A (pt) Novos compostos imidazola substituìdos
DE69730820D1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
DK1242452T3 (da) Kimære natriuretiske peptider
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
SV2002000506A (es) Compuestos de pirimidina pirrolo[2,3-d]ref. pc11027abtc/bb
ID23374A (id) Halogenopirimidin
DE69932397D1 (de) Zusammensetzung zur äusserlichen verwendung
DE69919537D1 (de) Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
DE69709561D1 (de) Östrogen-Rezeptor
AU9744298A (en) Substituted tetrahydronaphthaline and analogous compounds
DE69708848D1 (de) Mischung von erdalkalialkylarylsulfonaten, ihre verwendung als schmierölzusatz und herstellungsmethode
TW200615283A (en) Cationic polymers containing 2-hydroxyethyl methacrylate as promoters for ASA sizing
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
DE69817319D1 (de) Silanyltriazine als Lichtschutzmittel
DE60306672D1 (de) Verwendung von metallkomplexverbindungen als oxidationskatalysatoren
DE59811437D1 (de) Oxiranyl-triazolinthione und ihre verwendung als mikrobizide
BG104291A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties